GlassScriptPhysician profile
Haoran Li
NPI 1679094700
$623.31
in general payments reported to CMS, 2019-2025
11 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $107 · 2024: $161 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.36 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $244.04 | 2023-2024 | Cabometyx |
| Caris Mpi, INC. | $112.56 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $99.95 | 2025 | Erleada |
| Amgen INC. | $43.18 | 2025 | Imdelltra (Amg757) |
| Taiho Oncology, INC. | $34.21 | 2025 | |
| Abbvie INC. | $33.63 | 2025 | |
| Astellas Pharma Global Development | $31.73 | 2025 | Padcev |
| Vivus LLC | $24.01 | 2024 | Qsymia |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haoran Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.